Endologix, Inc. (ELGXQ)
Stock Price Chart
Key Info
| Market Cap | 1.70M |
| Revenue (ttm) | 124.88M |
| Net Income (ttm) | -59.80M |
| Shares Out | 20.66M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 13, 2020 |
| Last Price | $0.0825 |
| Previous Close | $0.0810 |
| Change ($) | 0.0015 |
| Change (%) | 1.85% |
| Day's Open | 0.0810 |
| Day's Range | 0.0800 - 0.1000 |
| Day's Volume | 479,864 |
| 52-Week Range | 0.0600 - 0.1340 |
More Stats
| Market Cap | 1.70M |
| Enterprise Value | 185.82M |
| Earnings Date (est) | Oct 28, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 20.66M |
| Float | 14.25M |
| EPS (basic) | n/a |
| EPS (diluted) | n/a |
| FCF / Share | -1.97 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 343,574 |
| Short Ratio | 0.91 |
| Short % of Float | 2.02% |
| Beta | 0.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 0.01 |
| PB Ratio | 0.06 |
| Revenue | 124.88M |
| Operating Income | -54.22M |
| Net Income | -59.80M |
| Free Cash Flow | -40.77M |
| Net Cash | -184.12M |
| Net Cash / Share | -8.91 |
| Gross Margin | 72.94% |
| Operating Margin | -43.42% |
| Profit Margin | -47.90% |
| FCF Margin | -32.65% |
| ROA | -11.29% |
| ROE | -119.02% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 143 | 156 | 181 | 193 | 154 | 148 | 132 | 106 | 83.42 | 67.25 |
| Revenue Growth | -8.37% | -13.63% | -6.1% | 25.59% | 4.08% | 11.59% | 24.83% | 27.01% | 24.04% | - |
| Gross Profit | 91.09 | 91.92 | 121 | 124 | 102 | 106 | 99.51 | 80.66 | 64.67 | 52.22 |
| Operating Income | -42.55 | -68.19 | -41.82 | -95.07 | -52.91 | -29.15 | -10.37 | -21.89 | -18.42 | -4.22 |
| Net Income | -64.76 | -79.71 | -66.40 | -155 | -50.42 | -32.42 | -16.07 | -35.77 | -28.73 | 10.65 |
| Shares Outstanding | 16.85 | 8.79 | 8.33 | 8.10 | 6.77 | 6.52 | 6.26 | 5.98 | 5.66 | 4.89 |
| Earnings Per Share | -3.84 | -9.07 | -7.97 | -19.10 | -7.50 | -5.00 | -2.60 | -6.00 | -5.10 | 2.10 |
| Operating Cash Flow | -29.57 | -38.61 | -35.40 | -72.81 | -31.09 | -26.33 | 1.49 | -18.53 | -22.38 | -4.11 |
| Capital Expenditures | -0.46 | -0.60 | -1.17 | -2.80 | -4.19 | -13.46 | -2.86 | -2.24 | -3.03 | -0.86 |
| Free Cash Flow | -30.03 | -39.22 | -36.57 | -75.60 | -35.28 | -39.80 | -1.37 | -20.77 | -25.42 | -4.97 |
| Cash & Equivalents | 42.76 | 24.73 | 60.60 | 49.11 | 177 | 86.67 | 126 | 45.12 | 20.04 | 38.19 |
| Total Debt | 194 | 198 | 225 | 177 | 168 | 70.41 | 67.10 | - | - | - |
| Net Cash / Debt | -152 | -173 | -165 | -128 | 9.57 | 16.26 | 59.36 | 45.12 | 20.04 | 38.19 |
| Assets | 307 | 293 | 365 | 360 | 331 | 248 | 256 | 165 | 130 | 134 |
| Liabilities | 243 | 253 | 290 | 247 | 228 | 124 | 152 | 70.63 | 53.69 | 40.47 |
| Book Value | 63.86 | 39.65 | 75.06 | 113 | 103 | 124 | 105 | 94.47 | 76.57 | 93.90 |
Company Profile
Company Details
| Full Name | Endologix, Inc. |
| Country | United States |
| Employees | 488 |
| CEO | John Onopchenko |
Stock Information
| Ticker Symbol | ELGXQ |
| Stock Exchange | US OTC |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Unique Identifier | OTCMKTS: ELGXQ |
| IPO Date | June 20, 1996 |
Description
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California. On July 5, 2020, Endologix, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas. It is in joint administration with TriVascular Sales LLC.